SHARE- BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure of terms and conditions of share-based payment arrangement [line items]

Schedule of Expense Recognized in Financial Statements

The expense recognized in the Company's financial statements for services provided by employees and service-providers is as follows:

	Six months ended June 30,
	2020		2019
	Unaudited
Share-based compensation – Attributable to equity holders of the Company	$	68	$	338
Share-based compensation – Attributable to non-controlling interests		2,721		109
	$	2,789	$	447

Schedule of Compensation Cost of Equity-Based Awards

The total compensation cost related to all of the Company's equity-based awards, recognized during the presented periods was comprised as follows:

	Six months ended June 30,
	2020		2019
	Unaudited
Research and development, net	$	1,404	$	214
Business development		897		123
General and administrative		488		110
	$	2,789	$	447

Employees Consultants and Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Schedule of Number of Share Options

The following table summarizes the number of share options, the weighted average exercise price, and the changes that were made in the option plans to employees, consultants and directors of Evogene Ltd. as of June 30, 2020 and during the period then ended:

	2020
	Number of options			Weighted average exercise prices ($)
	Unaudited
Outstanding on January 1		4,335,017			7.08
Grants		790,000			1.10
Forfeited		(807,468	)		6.95
Outstanding on June 30		4,317,549			5.99
Exercisable on June 30		2,511,019			8.74

Subsidiaries Employees Consultants and Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Schedule of Number of Share Options

The following table summarizes the number of share options, the weighted average exercise price, and the changes that were made in the option plans to employees, consultants and directors of the Company's subsidiaries as of June 30, 2020 and during the period then ended:

	2020
	Number of options			Weighted average exercise prices ($)
	Unaudited
Outstanding on January 1,		460,038			0.13
Grants		775,848			1.94
Forfeited		(40,484	)		0.20
Outstanding on June 30,		1,195,402			1.31
Exercisable on June 30,		502,257			0.17